Cargando…

Surgical resection for hepatocellular carcinoma with portal vein tumor thrombus in the Asia-Pacific region beyond the Barcelona Clinic Liver Cancer treatment algorithms: a review and update

Portal vein tumor thrombus (PVTT) usually worsens prognosis of hepatocellular carcinoma (HCC), as characterized by aggressive disease progression, impaired liver function and tolerance to treatment. Conventionally, the European Association for the Study of the Liver (EASL) and the American Associati...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Jia-Zhou, Wang, Yan-Yan, Bai, Tao, Chen, Jie, Xiang, Bang-De, Wu, Fei-Xiang, Li, Le-Qun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696262/
https://www.ncbi.nlm.nih.gov/pubmed/29190996
http://dx.doi.org/10.18632/oncotarget.18735
_version_ 1783280413919150080
author Ye, Jia-Zhou
Wang, Yan-Yan
Bai, Tao
Chen, Jie
Xiang, Bang-De
Wu, Fei-Xiang
Li, Le-Qun
author_facet Ye, Jia-Zhou
Wang, Yan-Yan
Bai, Tao
Chen, Jie
Xiang, Bang-De
Wu, Fei-Xiang
Li, Le-Qun
author_sort Ye, Jia-Zhou
collection PubMed
description Portal vein tumor thrombus (PVTT) usually worsens prognosis of hepatocellular carcinoma (HCC), as characterized by aggressive disease progression, impaired liver function and tolerance to treatment. Conventionally, the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD) accepted the Barcelona Clinical Liver Cancer (BCLC) treatment algorithms, identifying PVTT as an absolute contra-indication of surgical resection for HCC. HCC-PVTT patients are offered sorafenib as the standard treatment. Evidently, SHARP and Asia-Pacific trials demonstrated that sorafenib only improves overall survival by approximately 3 months in patients with advanced HCC. Besides, BCLC treatment algorithm does not provide different therapeutic recommendations for different degree of PVTT, and only supports single treatment option for each stage of HCC rather than a combination of comprehensive treatments, which limited individual and best care for every HCC-PVTT patients. In the past few years, many surgeons do not restrict surgical resection to HCC with PVTT. There have been new reports demonstrated that surgical treatment is feasible for selected HCC-PVTT patients with resectable tumor and moderate liver function to prolong survival period and elevate life quality as long as PVTT limited to the first-order branch, whereas non-surgical treatments fail to provide comparable therapeutic effects. At present, guidelines on HCC management from mainland China, Japan, and Hong Kong have been updated and a consensus of Asia-Pacific experts has established that portal venous invasion is not an absolute contradiction of surgical resection for HCC. This review summarized the emerging data on surgical resection for HCC-PVTT patients beyond the BCLC treatment algorithms and discussed recent therapeutic conceptualchanges in the Asia-Pacific region.
format Online
Article
Text
id pubmed-5696262
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-56962622017-11-29 Surgical resection for hepatocellular carcinoma with portal vein tumor thrombus in the Asia-Pacific region beyond the Barcelona Clinic Liver Cancer treatment algorithms: a review and update Ye, Jia-Zhou Wang, Yan-Yan Bai, Tao Chen, Jie Xiang, Bang-De Wu, Fei-Xiang Li, Le-Qun Oncotarget Review Portal vein tumor thrombus (PVTT) usually worsens prognosis of hepatocellular carcinoma (HCC), as characterized by aggressive disease progression, impaired liver function and tolerance to treatment. Conventionally, the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD) accepted the Barcelona Clinical Liver Cancer (BCLC) treatment algorithms, identifying PVTT as an absolute contra-indication of surgical resection for HCC. HCC-PVTT patients are offered sorafenib as the standard treatment. Evidently, SHARP and Asia-Pacific trials demonstrated that sorafenib only improves overall survival by approximately 3 months in patients with advanced HCC. Besides, BCLC treatment algorithm does not provide different therapeutic recommendations for different degree of PVTT, and only supports single treatment option for each stage of HCC rather than a combination of comprehensive treatments, which limited individual and best care for every HCC-PVTT patients. In the past few years, many surgeons do not restrict surgical resection to HCC with PVTT. There have been new reports demonstrated that surgical treatment is feasible for selected HCC-PVTT patients with resectable tumor and moderate liver function to prolong survival period and elevate life quality as long as PVTT limited to the first-order branch, whereas non-surgical treatments fail to provide comparable therapeutic effects. At present, guidelines on HCC management from mainland China, Japan, and Hong Kong have been updated and a consensus of Asia-Pacific experts has established that portal venous invasion is not an absolute contradiction of surgical resection for HCC. This review summarized the emerging data on surgical resection for HCC-PVTT patients beyond the BCLC treatment algorithms and discussed recent therapeutic conceptualchanges in the Asia-Pacific region. Impact Journals LLC 2017-06-27 /pmc/articles/PMC5696262/ /pubmed/29190996 http://dx.doi.org/10.18632/oncotarget.18735 Text en Copyright: © 2017 Ye et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Review
Ye, Jia-Zhou
Wang, Yan-Yan
Bai, Tao
Chen, Jie
Xiang, Bang-De
Wu, Fei-Xiang
Li, Le-Qun
Surgical resection for hepatocellular carcinoma with portal vein tumor thrombus in the Asia-Pacific region beyond the Barcelona Clinic Liver Cancer treatment algorithms: a review and update
title Surgical resection for hepatocellular carcinoma with portal vein tumor thrombus in the Asia-Pacific region beyond the Barcelona Clinic Liver Cancer treatment algorithms: a review and update
title_full Surgical resection for hepatocellular carcinoma with portal vein tumor thrombus in the Asia-Pacific region beyond the Barcelona Clinic Liver Cancer treatment algorithms: a review and update
title_fullStr Surgical resection for hepatocellular carcinoma with portal vein tumor thrombus in the Asia-Pacific region beyond the Barcelona Clinic Liver Cancer treatment algorithms: a review and update
title_full_unstemmed Surgical resection for hepatocellular carcinoma with portal vein tumor thrombus in the Asia-Pacific region beyond the Barcelona Clinic Liver Cancer treatment algorithms: a review and update
title_short Surgical resection for hepatocellular carcinoma with portal vein tumor thrombus in the Asia-Pacific region beyond the Barcelona Clinic Liver Cancer treatment algorithms: a review and update
title_sort surgical resection for hepatocellular carcinoma with portal vein tumor thrombus in the asia-pacific region beyond the barcelona clinic liver cancer treatment algorithms: a review and update
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696262/
https://www.ncbi.nlm.nih.gov/pubmed/29190996
http://dx.doi.org/10.18632/oncotarget.18735
work_keys_str_mv AT yejiazhou surgicalresectionforhepatocellularcarcinomawithportalveintumorthrombusintheasiapacificregionbeyondthebarcelonacliniclivercancertreatmentalgorithmsareviewandupdate
AT wangyanyan surgicalresectionforhepatocellularcarcinomawithportalveintumorthrombusintheasiapacificregionbeyondthebarcelonacliniclivercancertreatmentalgorithmsareviewandupdate
AT baitao surgicalresectionforhepatocellularcarcinomawithportalveintumorthrombusintheasiapacificregionbeyondthebarcelonacliniclivercancertreatmentalgorithmsareviewandupdate
AT chenjie surgicalresectionforhepatocellularcarcinomawithportalveintumorthrombusintheasiapacificregionbeyondthebarcelonacliniclivercancertreatmentalgorithmsareviewandupdate
AT xiangbangde surgicalresectionforhepatocellularcarcinomawithportalveintumorthrombusintheasiapacificregionbeyondthebarcelonacliniclivercancertreatmentalgorithmsareviewandupdate
AT wufeixiang surgicalresectionforhepatocellularcarcinomawithportalveintumorthrombusintheasiapacificregionbeyondthebarcelonacliniclivercancertreatmentalgorithmsareviewandupdate
AT lilequn surgicalresectionforhepatocellularcarcinomawithportalveintumorthrombusintheasiapacificregionbeyondthebarcelonacliniclivercancertreatmentalgorithmsareviewandupdate